J&J’s CARVYKTI shows higher rates of minimal residual disease negativity

Johnson & Johnson “announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI significantly increased minimal residual disease, MRD, negativity rates in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone) or daratumumab, pomalidomide and dexamethasone. MRD is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. These results add to the overall survival benefits recently presented at the International Myeloma Society meeting earlier this year, as the first and only cell therapy to significantly extend OS versus standard therapies for patients with multiple myeloma.1 Findings were featured in an oral presentation at the 2024 American Society of Hematology Annual Meeting.” “CARVYKTI has established its significant impact on overall survival and improved progression-free survival compared to standard therapies,” said Rakesh Popat, M.D., University College London Hospitals, NHS Foundation Trust, London, UK, and lead study investigator.* “The MRD negativity results demonstrate deep responses compared to standard therapies for people living with multiple myeloma and further underscore the benefit of CARVYKTI, administered as a single infusion as early as second line.”